Loss of EZH2 function has been proposed to play a role in the effects elicited by other mutations found in MPN, including ASXL1 and SRSF2, suggesting EZH2 loss of function may contribute to the biology of disease in patients beyond those that have EZH2 mutations (57, 114). This evidence concerns the gene ASXL1 and myeloproliferative neoplasm.